Cardiol Therapeutics Inc Class A (CRDL.TO) is having a good trading day, with shares up 3.47%.
In the latest trading session, Cardiol's stock price increased to CA$1.49. This rise shows investor optimism, likely driven by recent news about the company's clinical trials and financing activities.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$168.30M
52W high
$2.33
52W low
$1.23
1W change
-5.88%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 316.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.00
+316.7% Upside
Current Price
C$1.44
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.8%
Annualized
90-Day Vol
58.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.20
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.36 | C$1.20 โ C$1.54 |
| 60 trading days | C$1.28 | C$1.07 โ C$1.52 |
| 90 trading days | C$1.20 | C$0.97 โ C$1.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol's recent financing and ongoing clinical trials, as these could be key drivers for future growth.
Stock rises 3.47% in a single day.
Cardiol Therapeutics' market cap is now CA$168.3 million, reflecting growing interest as the company moves forward with its clinical initiatives.
Bull case
The recent completion of a US$11.4 million financing round to support the MAVERIC Phase III trial puts Cardiol Therapeutics in a strong position for potential breakthroughs in heart disease treatment. Success in this area could greatly improve its standing in the market.
Bear case
However, despite the positive stock movement, the company still faces challenges. Its lack of profitability and dependence on external financing could be risky if the clinical trials donโt produce the expected results.
Recent Developments Fueling Growth
Cardiol Therapeutics recently wrapped up a US$11.4 million financing round, which is expected to extend its cash runway and support the MAVERIC Phase III trial. This trial is essential for developing new heart disease treatments, and positive results could significantly boost its stock performance.
Market Response and Future Outlook
The market's reaction to Cardiol's stock increase shows investor confidence in its strategic direction. As the company moves through its clinical trials, stakeholders will be watching closely. The outcomes could either strengthen or challenge its current valuation. Investors should stay alert for further announcements about trial results and the companyโs financial health.
Advertisement
